Eugenio Pucci

List of Publications by Year
in descending order

95 papers	4,558 citations	101543 36 h-index	110387 64 g-index
101 all docs	101 docs citations	101 times ranked	4427 citing authors

#	Article	IF	Citations
1	Advance Care Planning in Neurodegenerative Disorders: A Scoping Review. International Journal of Environmental Research and Public Health, 2022, 19, 803.	2.6	12
2	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	3.3	3
3	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	3.0	11
4	Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. Multiple Sclerosis Journal, 2021, 27, 695-705.	3.0	7
5	Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial. BMJ Open, 2021, 11, e052012.	1.9	4
6	The impact of the COVID-19 pandemic on people with neurological disorders: an urgent need to enhance the health care systemâ€™s preparedness. Neurological Sciences, 2021, 42, 799-804.	1.9	12
7	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.1	54
8	Construction of a resource for advance care planning in multiple sclerosis (ConCure-SM): Results of cognitive debriefing with users. Journal of the Neurological Sciences, 2021, 429, 118081.	0.6	0
9	Risk of secondary progressive multiple sclerosis: A longitudinal study. Multiple Sclerosis Journal, 2020, 26, 79-90.	3.0	52
10	Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype. Multiple Sclerosis Journal, 2020, 26, 1765-1774.	3.0	10
11	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	2.0	29
12	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	7.6	32
13	Conflicts of interest and Scientific Societies. Neurological Sciences, 2020, 41, 2095-2102.	1.9	4
14	There is an urgent need for palliative care specialists in MS â€“ Yes. Multiple Sclerosis Journal, 2019, 25, 1710-1711.	3.0	4
15	Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. Frontiers in Neurology, 2019, 10, 916.	2.4	21
16	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis. The Cochrane Library, 2019, 5, CD009903.	2.8	7
17	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 458-468.	1.9	71
18	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders, 2019, 28, 235-243.	2.0	35

#	Article	IF	Citations
19	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	7.4	336
20	Management of psychogenic nonâ€epileptic seizures: a multidisciplinary approach. European Journal of Neurology, 2019, 26, 205.	3.3	64
21	Antiâ€inflammatory diseaseâ€modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. European Journal of Neurology, 2019, 26, 363-370.	3.3	12
22	Reply to: Comment on Y.D. Fragoso et al.: â€œLymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimodâ€•[Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	2.0	0
23	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders, 2018, 19, 105-108.	2.0	22
24	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis Journal, 2018, 24, 642-652.	3.0	37
25	No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. Journal of Neurology, 2018, 265, 2851-2860.	3.6	43
26	Silent lesions on MRI imaging â€“ Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1569-1577.	3.0	8
27	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences, 2018, 391, 72-76.	0.6	22
28	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurology, 2018, 75, 1407.	9.0	20
29	Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 266-276.	3.0	30
30	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 196-203.	1.9	49
31	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	10.2	134
32	Prognostic indicators in pediatric clinically isolated syndrome. Annals of Neurology, 2017, 81, 729-739.	5.3	34
33	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 2017, 89, 1050-1059.	1.1	38
34	Data quality evaluation for observational multiple sclerosis registries. Multiple Sclerosis Journal, 2017, 23, 647-655.	3.0	64
35	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis Journal, 2017, 23, 1346-1357.	3.0	18
36	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 2017, 140, 2426-2443.	7.6	94

#	Article	IF	Citations
37	Defining secondary progressive multiple sclerosis. Brain, 2016, 139, 2395-2405.	7.6	281
38	Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology, 2016, 23, 729-736.	3.3	21
39	Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1343-1349.	1.9	63
40	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	1.6	33
41	Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1133-1137.	1.9	76
42	Predictors of longâ€term disability accrual in relapseâ€onset multiple sclerosis. Annals of Neurology, 2016, 80, 89-100.	5.3	158
43	Need for palliative care for neurological diseases. Neurological Sciences, 2016, 37, 1581-1587.	1.9	28
44	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 520-532.	3.0	34
45	Switch to natalizumab versus fingolimod in active relapsingâ€“remitting multiple sclerosis. Annals of Neurology, 2015, 77, 425-435.	5.3	143
46	<scp>BREMSO</scp>: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology, 2015, 22, 981-989.	3.3	32
47	Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology, 2015, 72, 405.	9.0	100
48	Defining reliable disability outcomes in multiple sclerosis. Brain, 2015, 138, 3287-3298.	7.6	162
49	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1159-1171.	3.0	36
50	Natalizumab Treatment in Multiple Sclerosis Patients: A Multicenter Experience in Clinical Practice in Italy. International Journal of Immunopathology and Pharmacology, 2014, 27, 147-154.	2.1	23
51	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 739-746.	3.0	148
52	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency in people with multiple sclerosis: a summary of a Cochrane systematic review. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 405-410.	1.9	10
53	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain, 2013, 136, 3609-3617.	7.6	140
54	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. PLoS ONE, 2013, 8, e63480.	2.5	26

#	Article	IF	Citations
55	Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatric Disease and Treatment, 2013, 9, 893.	2.2	28
56	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Multiple Sclerosis Journal, 2012, 18, 974-982.	3.0	56
57	The Kurtzke EDSS rank stability increases 4â€…years after the onset of multiple sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 305-310.	1.9	37
58	Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis patients. The Cochrane Library, 2012, 12, CD009903.	2.8	3
59	Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences, 2012, 318, 94-99.	0.6	35
60	Persistent vegetative state: an ethical reappraisal. Neurological Sciences, 2012, 33, 695-700.	1.9	2
61	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS ONE, 2012, 7, e38661.	2.5	35
62	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS ONE, 2012, 7, e48078.	2.5	166
63	Natalizumab for relapsing remitting multiple sclerosis. The Cochrane Library, 2011, , CD007621.	2.8	55
64	Ethical issues in end of life treatments for patients with dementia. European Journal of Neurology, 2010, 17, 774-779.	3.3	27
65	The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. Multiple Sclerosis Journal, 2010, 16, 100-111.	3.0	50
66	An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Multiple Sclerosis Journal, 2010, 16, 1393-1405.	3.0	64
67	Understanding information on clinical trials by persons with Alzheimerâ€™s dementia. A pilot study. Aging Clinical and Experimental Research, 2009, 21, 158-166.	2.9	7
68	Responsiveness of patient reported outcome measures in multiple sclerosis relapses: the REMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 1023-1028.	1.9	42
69	Short-term combination of glatiramer acetate with IV steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsingâ€“remitting multiple sclerosis. Journal of the Neurological Sciences, 2008, 266, 44-50.	0.6	11
70	Participation in medical decision-making: Attitudes of Italians with multiple sclerosis. Journal of the Neurological Sciences, 2008, 275, 86-91.	0.6	63
71	Communicating the diagnosis of multiple sclerosis - a qualitative study. Multiple Sclerosis Journal, 2007, 13, 763-769.	3.0	77
72	Amantadine for fatigue in multiple sclerosis. The Cochrane Library, 2007, , CD002818.	2.8	99

#	Article	IF	Citations
73	Ethical questions in the treatment of subjects with dementia. Part I. Respecting autonomy: awareness, competence and behavioural disorders. Neurological Sciences, 2007, 28, 216-231.	1.9	26
74	Message for caregivers of dementia with Lewy bodies patients: hallucinations can be pleasurable for your patient. Cope with your embarrassment and empathize. European Journal of Neurology, 2006, 13, 666-666.	3.3	3
75	What do Italians at high risk of stroke know about ischaemic stroke? A survey among a group of subjects undergoing neuro-sonographic examination. Neurological Sciences, 2006, 27, 7-13.	1.9	15
76	Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with NAb. Multiple Sclerosis Journal, 2006, 12, 72-76.	3.0	42
77	Development of an ELISA Test for Determination of the Urinary Trypsin Inhibitor: Analytical Performance and Applications. Journal of Immunoassay and Immunochemistry, 2005, 26, 43-56.	1.1	2
78	Italian version of the Chicago multiscale depression inventory: translation, adaptation and testing in people with multiple sclerosis. Neurological Sciences, 2004, 24, 375-383.	1.9	37
79	General practitioners facing dementia: are they fully prepared?. Neurological Sciences, 2004, 24, 384-389.	1.9	37
80	Why physicians need to look more closely at the use of complementary and alternative medicine by multiple sclerosis patients. European Journal of Neurology, 2004, 11, 263-267.	3.3	41
81	Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. Journal of the Neurological Sciences, 2004, 222, 99-104.	0.6	122
82	Corrigendum to â€œComputer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trialâ€•[J. Neurol. Sci. 222 (2004) 99â€“104]. Journal of the Neurological Sciences, 2004, 224, 113.	0.6	1
83	Is the internet transforming the physician-consumer relationship? Preliminary data in a neurological setting. European Journal of Neurology, 2003, 10, 192-192.	3.3	15
84	Relatives' attitudes towards informing patients about the diagnosis of Alzheimer's disease. Journal of Medical Ethics, 2003, 29, 51-54.	1.8	43
85	Aminopyridines for symptomatic treatment in multiple sclerosis. The Cochrane Library, 2002, , .	2.8	37
86	Information and Competency for Consent to Pharmacologic Clinical Trials in Alzheimer Disease: An Empirical Analysis in Patients and Family Caregivers. Alzheimer Disease and Associated Disorders, 2001, 15, 146-154.	1.3	35
87	Cytochemistry of Intraplatelet Ca++ Spots as a Peripheral Marker of Age-related Brain Impairment. Annals of the New York Academy of Sciences, 2000, 903, 164-166.	3.8	3
88	Topographical Disorientation Consequent to Amnesia of Spatial Location in A Patient with Right Parahippocampal Damage. Cortex, 2000, 36, 427-434.	2.4	37
89	Absence of HHV-6 and HHV-7 in cerebrospinal fluid in relapsing-remitting multiple sclerosis. Acta Neurologica Scandinavica, 2000, 101, 224-228.	2.1	46
90	EEG power spectrum differences in early and late onset forms of Alzheimer's disease. Clinical Neurophysiology, 1999, 110, 621-631.	1.5	63

#	Article	IF	Citations
91	EEG spectral analysis in Alzheimer's disease and different degenerative dementias. Archives of Gerontology and Geriatrics, 1998, 26, 283-297.	3.0	31
92	Hippocampus and Parahippocampal Gyrus Linear Measurements Based on Magnetic Resonance in Alzheimerâ€™s Disease. European Neurology, 1998, 39, 16-25.	1.4	28
93	EEG power spectrum typical of vascular dementia in a subgroup of Alzheimer patients. Archives of Gerontology and Geriatrics, 1996, 23, 139-151.	3.0	18
94	An EEG power index (eyes open vs. eyes closed) to differentiate Alzheimer's from vascular dementia and healthy ageing. Archives of Gerontology and Geriatrics, 1996, 22, 245-260.	3.0	12
95	EEG spectral analysis in vascular and Alzheimer dementia. Electroencephalography and Clinical Neurophysiology, 1995, 94, 313-325.	0.3	93